Firm News

Home 9 News Item 9 Wiggin and Dana Advises BioArctic AB in research and collaboration agreement with Eli Lilly and Company

Wiggin and Dana Advises BioArctic AB in research and collaboration agreement with Eli Lilly and Company

June 23, 2026

Wiggin and Dana recently represented BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) in connection with its research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Lilly drug candidate in neurodegeneration. Under the agreement, BioArctic will receive a $30 million up-front payment and will be eligible to receive additional milestone payments of up to $770 million plus tiered mid-single digit royalties.

The Wiggin and Dana deal team consisted of Toby Bannon and Kelsey Loomis.

To learn more and read the official press release, please click here.

Firm Highlights